STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke

Coverage, in order

1. 3d ago
   first FDA Drug Safety / Drugs feed indie

   FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk

   FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.

2. 3d ago
   
   STAT News indie

   STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke

   The Food and Drug Administration on Monday approved Bayer’s drug to reduce recurrence of stroke, making available the first in a novel class of medications that hold the promise of preventing blood clots more safely. Many blood thinners aren’t used in this setting due to their increased risk of…

3. 3d ago
   Life Science Sweden Sweden indie

   FDA approves Bayer’s first-in-class stroke drug
4. 3d ago
   Pharmaphorum UK indie

   Bayer bags FDA green light for stroke drug Sunharbo

   Bayer bags FDA green light for stroke drug Sunharbo Phil.Taylor Tue, 10/11/2026 - 09:36

5. 3d ago
   
   Clinica.bg BG indie bg

   FDA approves a new drug against recurrent strokeFDA одобри нов медикамент срещу повторен инсулт

   Tablets cut recurrent ischaemic stroke risk by 26%.Таблетките намаляват с 26% риска от повторен исхемичен инцидент, съобщиха от Агенцията

6. 3d ago
   
   Medical Dialogues India obscure

   FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk

   The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke…

7. 2d ago
   
   MedCity News indie study

   FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke

   Bayer’s asundexian, brand name Sunharbo, is the first FDA-approved drug in a new class cardiovascular medicines Approval of the once-daily pill covers secondary stroke prevention in adults.

8. 1h ago
   
   Cardiovascular Business indie

   FDA approves first-in-class drug for secondary stroke prevention

   An FDA statement called the new approval of Bayer's asundexian a "meaningful advance for patients and healthcare providers seeking a new option for secondary stroke prevention."

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.